secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2022-08-12T23:59:59+00:00
Accession:  0001628280-22-022587
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE Therapeutics Q2 2022 net loss $8.5M, improved from $19.9M YoY
------------------------------------------------------------------

- GAAP loss from continuing operations $8.2M in Q2 2022 vs $10.7M in Q2 2021.
- Adjusted net loss (non-GAAP) $7.3M in Q2 2022 vs $18.0M in prior year.
- Six-month adjusted net loss $1.8M vs $36.1M in H1 2021, driven by discontinued operations.
- CEO highlights BET inhibitor platform potential for immuno-inflammatory diseases.
- No revenue reported; company remains in development stage.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000162828022022587/0001628280-22-022587-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000162828022022587/mnlo-20220812.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-022587

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer